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Pluripotent stem cells derived from preimplantation
embryos, primordial germ cells or teratocarcinomas are
currently unique in undergoing prolonged symmetrical
self-renewal in culture. For mouse embryonic stem (ES)
cells, self-renewal is dependent on signals from the
cytokine leukaemia inhibitory factor (LIF) and from
either serum or bone morphogenetic proteins (BMPs). In
addition to the extrinsic regulation of gene expression,
intrinsic transcriptional determinants are also required for
maintenance of the undifferentiated state. These include
Oct4, a member of the POU family of homeodomain
proteins and a second recently identified homeodomain
protein, Nanog. When overexpressed, Nanog allows ES
cells to self-renew in the absence of the otherwise
obligatory LIF and BMP signals. Although Nanog can
act independent of the LIF signal, a contribution of both
pathways provides maximal self-renewal efficiency.
Nanog function also requires Oct4. Here, we review
recent progress in ES cell self-renewal, relate this to the
biology of teratocarcinomas and offer testable hypotheses
to expose the mechanics of ES cell self-renewal.
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Introduction
The first differentiative events during mouse embryo-
genesis partition the embryo into extraembryonic and
embryonic components (Gardner, 1983). The embryonic
component, located on the interior and referred to as the
inner cell mass (ICM), is the source of all the tissues of
the developing embryo, fetus and ultimately adult
organism. The ICM is also the source of embryonic
stem (ES) cells (Brook and Gardner, 1997; Evans and
Kaufman, 1981; Martin, 1981). The value of ES cells is
derived from their capacity to contribute to all three
germ layers, ectoderm, endoderm and mesoderm. This
can be demonstrated in vitro in response to particular
differentiative regimes or more strikingly when ES cells
are introduced into a blastocyst. In this case, ES cell
derivatives can colonize all the tissues to produce a
chimaera in which cells derived from the host ICM and
from the injected ES cells are intimately associated
throughout the organism (Beddington and Robertson,
1989). When the ES cells colonize the germline, they can
pass their genetic inheritance to the next generation
(Bradley et al., 1984). This latter property has been
extensively exploited in the analysis of gene function in
vivo (van der Weyden et al., 2002). The ability of ES cells
to differentiate into all germ layers of the organism is
one of their defining features and is an attribute that we
define as pluripotency. Some authors describe ES cells as
totipotent, but this overlooks the fact that they do not
ordinarily give rise to trophectoderm nor do they
produce primitive endoderm in vivo. Other cells some-
times referred to as pluripotent such as haemopoietic
stem cells can be defined more rigorously as multipotent,
since they can differentiate into a restricted but distinct
range of cell types. The fact that ES cells can be derived
from and reintroduced into the ICM does not necessa-
rily mean that ES cells and cells of the ICM are
equivalent. The ICM exists only transiently and does
not operate as a stem cell compartment in vivo. Thus, it
is not evident that cells identical to ES cells ever exist in
vivo. Rather, these remarkable cells may arise through
selection and adaptation to the culture environment
(Smith, 2001; Buehr and Smith, 2003). A second
defining feature of ES cells is the ability to undergo cell
divisions without differentiation so as to produce
identical pluripotent progeny. This property is referred
to as self-renewal and in ES cells occurs via symmetrical
cell division. At present, we do not know if asymmetric
division ever occurs in ES cell culture.
In this review, we first summarize pertinent findings
from the seminal work conducted on teratocarcinomas
and the origin of embryonal carcinoma (EC) cells. We
then discuss the molecular basis of self-renewal of ES
cells both in terms of what the literature provides
evidence for and in terms of hypotheses that may help
formulate experimental tests. Finally, we relate recent
findings on ES cell biology to the stem cell component of
teratocarcinomas.
Teratocarcinomas and the origin of EC cells
The intellectual framework for investigations into the
biology of ES cells was laid during the 1970s when the
imagination of many investigators had been captured by
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observations made on teratocarcinomas and the plur-
ipotent cells that they harbour, EC cells. Here, we
simply summarize a few points about these tumours; for
fuller discussions, the reader is referred to some excellent
reviews (Stevens, 1983; Andrews, 2002). In pioneering
work carried out from the mid-1950s, Stevens demon-
strated that teratomas arise spontaneously in the testes
of B1% of mice of strain 129. These tumours can also
form in other strains of mice when male genital ridges
from embryos at gestational days 11–13 are transplanted
to the testes of adult recipients. Teratomas contain a
mixture of differentiated cell types derived from all three
germ layers that are present in the tumour mass in an
organizationally deranged manner. These tumours can
either be benign or malignant. In the latter case, they are
referred to as teratocarcinomas. The cell biological
distinction is that teratocarcinomas contain undiffer-
entiated stem cells allowing them to form tumours when
transplanted into a secondary recipient. Subsequent
studies demonstrated that the origin of experimentally
induced teratocarcinomas was not restricted to male
germ cells; transplantation of pregastrulation stage
embryos as young as the two-cell stage to either testes
or kidney also results in teratocarcinoma formation
(Stevens, 1968, 1970; Solter et al., 1970). Interestingly, in
this case it was possible to establish teratocarcinomas
from a strain (C3H/H) that would not produce
teratocarcinomas when genital ridges were transplanted
(Solter et al., 1970). The cellular origin of teratocarci-
noma-forming cells within the pregastrulation embryo
was shown to be the epiblast (Diwan and Stevens, 1976).
The clonal potency of teratocarcinoma stem cells was
established by the formation of secondary teratocarci-
nomas upon transfer of individual undifferentiated cells
(Kleinsmith and Pierce, 1964). These undifferentiated
cells can also be cultured in vitro to give rise to lines of
EC cells (Finch and Ephrussi, 1967). Interestingly,
although EC cells form malignant teratocarcinomas
when transplanted to ectopic sites, when reintroduced
into a blastocyst, they may sometimes become incorpo-
rated into the embryo and contribute to tissues of the
developing fetus (Brinster, 1974). This indicates that the
proliferation of undifferentiated EC cells can be brought
under control in response to the appropriate environ-
mental cues. Conversely, proliferation of the epiblast
becomes deregulated in an ectopic environment to
generate a teratocarcinoma, indicating that the pluripo-
tent embryo founder cells have an intrinsic propensity
for extended proliferation.
EC cells are almost always aneuploid and most do not
contribute to chimaeras nor differentiate well in vitro.
Nevertheless, it was this work on teratocarcinoma stem
cells that informed experiments leading to the isolation
of pluripotent ES cells. The success of these experiments
hinged on the use of a supporting layer of fibroblasts
upon which to explant the embryonic material; the
maintenance of pluripotent EC lines had been found to
be favoured by co-culture with fibroblasts (Martin and
Evans, 1975). In the early 1980s, the same workers
reported the isolation of stem cell lines directly from
preimplantation embryos explanted into culture without
an intervening tumour phase (Evans and Kaufman,
1981; Martin, 1981). Initially, these cells were character-
ized as teratocarcinoma stem cell lines. However, when
they were reintroduced into mouse embryos and found
to contribute widely to tissues of the resulting chimaera
and subsequently to pass through the germline, it
became clear that they differed qualitatively from EC
cells in that their quasi-tumorigenic status could be
entirely controlled (Bradley et al., 1984). These cells are
now known as ES cells.
Molecular basis for ES cell self-renewal
Signalling through cytokine receptors ES cells can be
propagated under culture conditions similar to those
used for EC cells; in other words, in the presence of
serum and in co-culture with a layer of fibroblasts. An
indication that the fibroblasts act by producing a signal
that inhibits ES cell differentiation (Smith and Hooper,
1983) was substantiated by the ability of medium
conditioned by the Buffalo rat liver cell line to replace
the fibroblast requirement (Smith and Hooper, 1987).
Subsequent fractionation of the conditioned medium
identified the active component as leukaemia inhibitory
factor (LIF) (Smith et al., 1988; Williams et al., 1988).
Although many workers continue to use feeders, it is
worth noting that the first targeted germline modifica-
tions generated via ES cells used feeder-free conditions
(Hooper et al., 1987; Thompson et al., 1989) and
increasing numbers of investigators now use cell lines
such as E14Tg2a and CGR8, which have little or no
history of feeder co-culture.
LIF is a member of the IL6 family of cytokines that
signal through receptor complexes including the trans-
membrane receptor, gp130 (reviewed in Heinrich et al.,
2003). LIF binds directly to a receptor (LIFR) that
contains a long cytoplasmic tail with homology to
gp130. The LIF–LIFR complex then recruits gp130, to
form a trimeric complex (Zhang et al., 1997). IL-6, in
contrast, binds to an IL6 receptor (IL6R) lacking a
significant intracellular domain and dependent on the
recruitment and dimerization of gp130 in order to
mediate downstream signalling. ES cells do not express
IL6R and so cannot respond to IL6. However, if a
soluble form of IL6R is supplied to ES cells along with
IL6, then the cells can be propagated in the undiffer-
entiated state (Yoshida et al., 1994) and can in fact be
isolated de novo (Nichols et al., 1994). This indicates that
the requirement for LIFR is not absolute and can be
substituted for by a second gp130 molecule. The
signalling events occurring downstream of gp130 in ES
cells have been reviewed previously (Burdon et al.,
1999a). In summary, the key positive event following
gp130 dimerization is the tyrosine phosphorylation,
dimerization and nuclear translocation of the signal
transducer and activator of transcription, STAT3 (Niwa
et al., 1998). Evidence that activation of STAT3 is
sufficient for ES cell self-renewal has been presented
(Matsuda et al., 1999). These studies used a chimaeric
STAT3-estrogen receptor that could be dimerized by
treatment of cells with 4-OH-tamoxifen. However, these
ES cell self-renewal
I Chambers and A Smith
7151
Oncogene
analyses were conducted at relatively high cell density
leaving open the possibility of contributions from
autocrine factors, including LIF, to ES cell self-renewal.
Moreover, we now know that the additional presence of
serum contributes self-renewal signals, establishing that
STAT3 is not strictly sufficient for self-renewal (Ying
et al., 2003).
Other extrinsic regulators of ES cell self-renewal
Bone morphogenetic protein (BMP)/GDF It has
recently been demonstrated that BMP4, BMP2 or
GDF6 can replace the requirement for serum both
during clonal propagation of ES cells and during their
de novo derivation (Ying et al., 2003). This suppression
of differentiation appears to be restricted to BMP
receptor agonists as it is not shared by other members
of the TGF-b superfamily, specifically activin and TGF-
b1. The BMP/GDF function is dependent on co-
stimulation with LIF; in the presence of BMP alone
cells are driven into non-neural differentiation. In LIF
without serum or BMP, there is limited self-renewal and
neural differentiation ensues. BMP treatment suppresses
neural determination and in combination with LIF is
sufficient to sustain ES cell self-renewal without feeders
or serum factors. BMP induces expression of members
of the Id family of negative transcriptional modulators
in various cell types (Nakashima et al., 2001; Ruzinova
and Benezra, 2003). This induction of Ids also occurs in
ES cells and is the critical contribution of BMP/GDF
signalling to ES cell self-renewal, since constitutive
expression of Id1, Id2 or Id3 circumvents the BMP/
GDF requirement. It is possible that Id molecules act to
prevent the effects of precocious expression of the
proneural basic helix–loop–helix (bHLH) transcription
factors such as the Mash genes in ES cells. Alternatively,
the Ids may exert their effect by interaction with non-
bHLH proteins, such as Pax factors (Norton, 2000).
Wnt Wnts also appear to suppress neural determina-
tion of ES cells (Aubert et al., 2002). Recently, evidence
has been presented that the wnt pathway could be
involved in the short-term maintenance of pluripotency
of both mouse and human ES cells (Sato et al., 2004).
This assertion relies heavily on the use of a recently
discovered pharmacological inhibitor of glycogen
synthase kinase-3 and is thus subject to the usual
specificity provisos with regard to chemical inhibitors
(Bain et al., 2003). Moreover, GSK-3 is involved in
more than just wnt signalling (Frame and Cohen, 2001).
RT–PCR analysis suggests that wnts are expressed
during preimplantation development (Lloyd et al., 2003)
and may be expressed in undifferentiated ES cells (Lako
et al., 2001). However, the acceptance of a role for wnts
in ES cell self-renewal will require the demonstration
that specific activation of wnt signalling allows main-
tenance of ES cell pluripotency during clonal propaga-
tion of ES cells through multiple passages.
Other unidentified factors The requirement of LIF for
maintenance of pluripotency of ES cells represents
something of a paradox. Mutations in genes encoding
LIF-like cytokines, components of the LIF receptor
or STAT3 do not produce phenotypes in embryos
during the period of establishment and maintenance of
pluripotency in the mouse embryo. This is despite
reciprocal blastocyst expression patterns of LIF and
LIFR with LIFR being expressed in the ICM (Nichols
et al., 1996) and of clear evidence that these molecules play
critical roles in the in vitro maintenance of pluripotency.
The fact that mutations in gp130 and, to a lesser extent,
LIFR, impair the ability of preimplantation embryos to
survive a period of implantational delay (Nichols et al.,
2001) suggests a resolution of this conundrum. Delayed
implantation is a physiological adaptation to the
presence of a suckling litter that allows embryos to
persist for several weeks without implanting; upon
cessation of suckling, the embryos implant and devel-
opment proceeds normally. gp130 mutants lose the
epiblast component after 6 days in delay and can no
longer generate a fetus on implantation. This indicates
that there is a specific and obligate requirement for
gp130-mediated signalling in order to extend the period
of pluripotency. Nevertheless, the lack of a phenotype in
the unperturbed embryo suggest that other mechanisms
are normally responsible for the maintenance of
pluripotent identity. The ability of lif/ ES cells to
self-renew in the presence of neutralizing gp130 anti-
body provided evidence of an additional pathway for ES
cell maintenance (Dani et al., 1998). This ES cell self-
renewal factor (ESRF) was detectable in the conditioned
medium produced by a parietal endoderm-like cell line.
However, this activity has proven refractory to standard
protein purification and COS cell expression cloning
strategies. The production of LIF by fibroblast feeder
cells suggests that LIF is a major determinant of the
ability of feeder cells to support ES cell self-renewal. In
fact, fibroblasts carrying deletions in LIF have a reduced
capacity to support ES cell self-renewal (Stewart et al.,
1992). We reasoned that if the only activity supplied by a
feeder layer of primary fibroblasts was LIF, then ES
cells unable to respond to LIF due to deletion of both
lifr alleles would completely differentiate when co-
cultured with fibroblasts. Indeed, a reduced number of
alkaline phosphatase positive colonies was formed in
this case (Figure 1), underscoring the role of LIFR in
this system. However, undifferentiated colony forma-
tion was not completely inhibited, indicating that there
are LIFR-independent means by which fibroblasts can
support ES cell self-renewal.
Intrinsic determinants of ES cell self-renewal
Oct4 Oct4 is a member of a group of transcription
factors that bind the octamer sequence ATGCAAAT. In
addition, Oct4 can act on a subset of target genes by
binding to alternative A/T-rich sites (Saijoh et al., 1996).
Expression of Oct4 occurs in the unfertilized egg and the
early embryo prior to segregation of the ICM from the
trophectoderm (Pesce and Scholer, 2001). Oct4 is
zygotically expressed during cleavage stages (Palmieri
et al., 1994). Subsequent to the allocation of ICM cells,
ES cell self-renewal
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Oct4 is downregulated in the trophectoderm but is
readily detected in the ICM. Expression of Oct4 is
maintained in the epiblast of pre- and postimplantation
embryos before becoming restricted to the migratory
primordial germ cells where it persists through the
formation of the genital ridges in both sexes.
Mouse embryos in which Oct4 is mutated, form
superficially normal but developmentally compromised
blastocysts. Ordinarily, after blastocyst formation, a
layer of primitive endoderm forms on the blastocoelic
surface (Gardner, 1983). When Oct4/ embryos are
allowed to attach in vitro and outgrow on plastic, the
colonies that form consist entirely of trophectodermal
cells (Nichols et al., 1998). The failure of Oct4 mutant
outgrowths to differentiate into primitive endoderm or
definitive germ layers indicates a severe defect in the
potency of the cells that become allocated to the interior
in the absence of Oct4. Experiments performed in vitro
using ES cells carrying an Oct4 cDNA under tetracy-
cline control showed that when Oct4 is deleted from ES
cells transdifferentiation into trophectodermal cells
occurs (Niwa et al., 2000). This demonstrates that
Oct4 is continuously required by ES cells in order to
maintain their pluripotent identity. Furthermore, when
the level of Oct4 was artificially raised by more than
50% of wild-type levels, a significant proportion of the
cells formed differentiated colonies expressing markers
of endodermal and mesodermal origin. This finding
suggests that a factor that acts co-operatively with Oct4
to direct expression of the ES cell transcriptome is
present at limiting amounts. One possibility is that this
factor interacts directly with Oct4 such that when Oct4
levels are raised it either becomes titrated away or
displaced from specific target genes.
In genetically unmanipulated ES cells, withdrawal of
LIF causes differentiation and leads to a coincident and
gradual reduction in Oct4 expression. This means that it
is not normally possible to examine the effect of Oct4
expression in the absence of LIF. However, in the cells
referred to above in which Oct4 expression is regulated
solely by tetracycline, LIF can be withdrawn without
reducing Oct4 expression. Under these conditions, the
cells differentiate. This establishes that Oct4 cannot act
alone to maintain pluripotency and that other factor(s)
whose activity is influenced by the gp130 pathway act in
combination with Oct4.
Sox2/FoxD3 Two transcription factors that may
interact with Oct4 and for which roles in pluripotency
have been proposed are FoxD3 and Sox2. Expression of
the forkhead transcription factor FoxD3 is detectable in
the blastocyst and later in the postimplantation egg
cylinder epiblast. Although interaction with Oct4 has
been claimed (Guo et al., 2002) evidence that FoxD3 is
involved in pluripotency remains indirect. Mutant
FoxD3 embryos survive until about E6.5 by which time
there is an obvious defect in the embryonic compart-
ment (Hanna et al., 2002). Thus, FoxD3 is required at a
stage beyond establishment and maintenance of a
pluripotent ICM.
Sox2 is a transcription factor containing a HMG
DNA-binding domain that plays an essential role in the
transcription of several Oct4 target genes (Niwa, 2001).
In the case of the FGF4 enhancer, which is the
best studied example, Sox2 and Oct4 bind to adjacent
sites within the enhancer and act synergistically to
stimulate transcription (Ambrosetti et al., 2000). Sox2
mutant embryos are present at E3.5, but by E6 Sox2/
implantation sites lack Oct4-expressing cells (Avilion
et al., 2003). Outgrowths of Sox2/ ICMs do not
sustain an epiblast component but, in contrast to Oct4
mutants, generate both trophectodermal and primitive
endodermal cell types. However, the situation here is
complicated by the persistence of maternal Sox2 protein.
It would be interesting to know whether Sox2/
embryos lacking maternal Sox2 protein would repro-
duce the Oct4-null phenotype. It would also be
informative to remove Sox2 from ES cells by condi-
tional deletion or siRNA ablation. Such studies may
reveal whether Sox2 is required to enable Oct4 to block
trophectodermal differentiation.
Nanog Recently, using either functional cDNA
expression cloning or an in silico differential expression
analysis, two groups independently identified a novel
intrinsic determinant of pluripotency (Chambers et al.,
2003; Mitsui et al., 2003). This is Nanog. Like Oct4, it is
a homeodomain containing protein. However, the
identity within the Nanog homeodomain to the home-
odomains of other mouse proteins is at best 50%. This is
too low to place Nanog in a previously identified family
(Kappen et al., 1993) and indicates that Nanog is a
divergent homeodomain protein. Nanog is expressed in
a quite restricted range of cell types and apparently only
in a subset of cells that express Oct4, including ES cells.
Nanog is not present in the unfertilized egg and
expression is not initiated at the onset of zygotic
transcription. Rather, Nanog expression is first detected
in morulae being most obvious in cells in the interior of
the embryo. High levels of Nanog mRNA persist in the
Figure 1 ES cells lacking LIFR self–renew in fibroblast co-culture.
1000 ES cells heterozygous or homozygous for deletion of the
lifr gene were plated onto a confluent 10 cm2 layer of irradiated
primary mouse embryonic fibroblasts in standard ES cell medium
lacking LIF. After 6 days incubation, undifferentiated ES cell
colonies were visualized by staining for alkaline phosphatase.
Alkaline phosphatase-positive colonies show a pink colouration
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early blastocyst, but interestingly Nanog expression
declines prior to implantation. This dynamic expression
pattern could indicate that downregulation of Nanog
may be important to avoid an uncontrolled expansion of
pluripotent cells. Following implantation, Nanog
mRNA is expressed in a subset of epiblast cells with
highest levels in the proximal posterior region; upon
entry into the primitive streak, Nanog mRNA is rapidly
downregulated (Hart et al., 2004 and our unpublished
data). Nanog is detectable in PGCs during migration to
and residence in genital ridges between days 9 and 13 of
gestation (Chambers et al., 2003 and unpublished)
To confirm that Nanog is capable of conferring
cytokine independent self-renewal, a Nanog transgene
flanked by loxP sites was integrated into otherwise
unmodified ES cells. When Nanog expressing cells were
taken through two passages at clonal density in the
presence of an LIF receptor antagonist (Vernallis et al.,
1997), self-renewing ES cells persisted, whereas similarly
treated parental cells completely differentiated. The
subsequent excision of the floxed Nanog cassette
restored LIF dependence. Blastocyst injection of the
Cre derivative cells showed contribution of donor cells
to the tissues of chimaeric mice, indicating that
pluripotency was maintained during the period of LIF-
independent ES cell self-renewal (Chambers et al., 2003).
These experiments also allowed a phenotypic compar-
ison of parental cells, Nanog-expressing cells and their
Cre derivatives. By all criteria, Cre derivative cells and
parental cells were indistinguishable establishing that
the phenotypic alterations in Nanog-expressing cells
were a consequence of Nanog expression and did not
result from some other mutation in the cells. In addition
to confirming that Nanog overexpression could direct
ES cell self-renewal under conditions in which they
would otherwise differentiate, biochemical analysis
indicated that Nanog overexpression does not effect
STAT3 activation nor does STAT3 activate Nanog
expression. Signals from gp130 include a negative
feedback mechanism whereby STAT3 induces expres-
sion of SOCS3, which then binds to gp130 and
inactivates signaling (Heinrich et al., 2003). The ability
of Nanog to function separately from the STAT3
pathway is further supported by the ability of Nanog-
overexpressing cells to self-renew in the presence of
constitutive SOCS3 expression (unpublished). Despite
being able to act separately, Nanog and STAT3 do act
synergistically to provide maximal self-renewal effi-
ciency. This is evident from the fact that Nanog-
overexpressing cells form pure stem cell colonies
at clonal density with significantly increased effi-
ciency when the cultures are supplemented with LIF
(Chambers et al., 2003, Figure 5).
Nanog function requires the continued presence of
Oct4. When ES cells that express Oct4 from the
tetracycline-regulated locus have their Oct4 transgene
repressed the cells differentiate along the trophectoder-
mal lineage. This effect can be prevented by transfecting
an Oct4 cDNA into the cells (Niwa et al., 2002) but not
by transfecting Nanog cDNA (Chambers et al., 2003).
This eliminates the possibility that Oct4 functions
simply to activate Nanog expression and establishes
that Nanog function requires Oct4. The fact that
overexpression of Nanog, in otherwise wild-type cells,
confers self-renewal implies that Nanog can determine
Oct4 expression. However, this effect is most probably
indirect. The requirement of Nanog for the expression of
the Oct4 gene was tested directly by examination of
blastocysts from a Nanogþ /Nanogþ / intercross.
The presence of Oct4 mRNA in all the embryos
indicates that Nanog is not essential for Oct4 expression
(I Chambers, A Smith, J Nichols and S Yamanaka,
unpublished data). The reciprocal experiment suggests
that Oct4 is not essential for the initiation of Nanog
expression. However, the relative kinetics of the expres-
sion of Oct4 and Nanog in the embryo and the presence
of a potential Oct4-binding site immediately adjacent to
a potential Sox2-binding sites in the Nanog promoter
suggest that Oct4 may contribute to the dynamic and/or
quantitative regulation of Nanog expression (Figure 2).
Molecules inhibitory to ES cell self-renewal
The activation of the STAT3 target gene SOCS3
represents a negative regulatory signal that is delivered
from gp130. SOCS3 is a member of the family of
suppressors of cytokine signaling, which act as classical
negative regulators to attenuate the signal leading to
their production. Members of the SOCS gene family
were isolated through an elegant functional strategy in
which M1 myeloid cells, which differentiate and stop
proliferation when treated with LIF, were transfected
with a cDNA library and screened for continued
proliferation in the presence of LIF (Starr et al., 1997).
Oct4 Sox2
 -190  ttacagcttc ttttgcatta caatgtccat ggtggaccct gcaggtggga
 -140  ttaactgtga attcacaggg ctggtggggc gtgggtgccg cctgggtgcc
  -90  tgggagaata gggggtgggt agggtaggag gcttgagggg ggaggagcag
  -40  gacctaccct ttaaatctat cgccttgagc cgttggcctt cagataggct
Figure 2 Sequence of the Nanog gene upstream from the transcription initiation site (indicated by the arrow). Matches to the
consensus binding site for Oct 4 (ATGCAAAT; 7/8) and Sox 2 (CTTTGT/AT/A; 6/7) are shown shaded in dark and light grey,
respectively. These sequences are juxtaposed relative to one another in the same manner as they are on known Oct 4/Sox 2 target genes
such as Utf1
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In ES cells, the only SOCS gene to be significantly
induced following gp130 stimulation is SOCS3 (unpub-
lished data). Evidence has been presented that SOCS3
overexpression in ES cells has an apoptotic effect (Duval
et al., 2000). This conclusion was based largely on the
observation of an absence of colonies following trans-
fection of a SOCS3 expression plasmid into ES cells. We
have also noted that when ES cells are transfected with
an expression plasmid driving SOCS3 at high levels,
there is a decrease in colony formation. However, this
may simply be due to non-specific effects of the
expression of a gene product at levels far in excess of
the physiological norm. Indeed, when SOCS3 is
expressed at a more modest level either from a weaker
episomal expression plasmid or from a tetracycline-
inducible locus, colonies do form in the presence of LIF,
but are morphologically differentiated (Figure 3) and do
not express alkaline phosphatase. A negative interfering
form of STAT3 (STAT3F) similarly directs ES cell
differentiation in the presence of LIF when over-
expressed (Niwa et al., 1998). In both cases, morpho-
logical differentiation is similar to that seen upon LIF
withdrawal or addition of LIF antagonist. This indicates
that the primary role of LIF is as a differentiation
inhibitor rather than a stem cell survival factor.
Induction of differentiation by GATA factors
Transcription factors that have been demonstrated to
induce ES cell differentiation into primitive endoderm
are GATA6 and GATA4 (Fujikura et al., 2002). These
molecules are unique to date in their ability to cause ES
cells to differentiate in an apparently uniform manner.
An interesting feature of the differentiation induced by
GATA4 and GATA6 is the positive feedback on the
endogenous gene expression seen when either transcrip-
tion factor is exogenously expressed in ES cells
(Fujikura et al., 2002). Both GATA4 and GATA6 are
also expressed, albeit at a lower level, following super-
transfection of ES cells with either Oct4 or STAT3F.
This could reflect heterogeneous differentiation. Alter-
natively, GATA expression may occur broadly in the
population but a threshold level may need to be
exceeded to initiate positive feedback and dictate uni-
form endodermal differentiation. A further point of note
from this work is the rapidity of loss of ES cell-specific
transcripts following induced GATA6 expression from a
tetracycline-responsive GATA6 transgene. The rate of
decline of Oct4 and Sox2 mRNAs was relatively
shallow, whereas the rate of disappearance of mRNAs
corresponding to the Oct4 target genes Rex1 and Utf1
(also a Sox2 target) was much more rapid. Of course, it
is possible that differences in the half-life of the mRNAs
underlie this effect. On the other hand, it could reflect
the rapid loss or functional inactivation of a positively
acting transcriptional coregulator of Rex1 and Utf1
expression.
Is there a relationship between GATA4/6 function and
Nanog?
As mentioned above, Yamanaka and co-workers used
an in silico differential display algorithm to identify
expressed sequence tags specifically expressed in
undifferentiated mouse ES cells. Importantly, several
of the identified genes were previously known to be
specifically expressed in ES cells, including Oct4 and
Rex1. More interesting, however, were the novel genes
(including Nanog) that Yamanaka’s group have subse-
quently gone on to analyse by targeted gene deletions.
Nanog/ embryos fail to develop following implanta-
tion (Mitsui et al., 2003). When ICMs from Nanog/
embryos were cultured in vitro, epiblast cells were not
evident. Instead, the outgrowths were composed entirely
of primitive endoderm-like cells. Furthermore, when
Nanog was deleted from ES cells, the resulting Nanog/
cell lines lost their ES cell character and displayed a
rounded morphology typical of parietal endoderm. This
assignment is underpinned by the expression of en-
dodermal rather than ES cell mRNAs in the Nanog/
cells. Taken together, these observations indicate that
Nanog functions to prevent primitive endodermal
differentiation.
Given the similar phenotypic consequences of over-
expression of GATA factors and elimination of Nanog,
this raises the question of whether Nanog acts either
partially or wholly by preventing the expression or
function of GATA6. As GATA6 can act as a positive
mediator of its own transcription, a small increase in
GATA6 expression may rapidly become amplified
(Fujikura et al., 2002). A DNA sequence to which
Nanog binds has been determined by SELEX.
Unsurprisingly, this sequence contains the core ATTA
sequence recognized by all homeodomain proteins.
Outwith this sequence, there is limited specificity. A
homeodomain-binding site exists in the GATA6 pro-
moter, which has been hypothesized to bind Nanog and
mediate repression of GATA6 expression (Mitsui et al.,
2003). Whether this sequence is indeed involved in the
regulation of GATA6 expression will require experi-
ments in which the GATA6 promoter is used to drive
expression of a reporter gene in ES cells. An alternative
method of demonstrating an antagonistic biological
effect of Nanog on GATA6 function would be to
Figure 3 Enforced expression of SOCS3 blocks self-renewal of ES
cells directed by LIF. E14/T cells were supertransfected with an
episomal expression plasmid (pPyHPGK-) containing no insert
(left) or SOCS3 ORF (right) and plated in the presence of LIF and
Hygromycin B. Colonies were photographed after 5 days of
selection
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examine the effect of expression of GATA6 from a
constitutive, heterologous promoter in Nanog-over-
expressing ES cells. If Nanog is found to block the
expression or activity of GATA6, an important next
question will be whether this is the only important
function of Nanog. This can be investigated by creating
Nanog/, GATA6/ cells and determining whether
they retain ES cell identity or differentiate.
Human ES cells
Human ES cells express Oct4 and Nanog. Orthologues
of Nanog have been identified in humans and rats and
cDNAs have been tested functionally in mouse ES cells;
both are capable of sustaining alkaline phosphatase-
positive colonies in the absence of LIF (Chambers et al.,
2003 and unpublished). The efficiency with which
human Nanog directs mouse ES cell self-renewal is
low compared with mouse Nanog, which probably
reflects divergence in the protein sequence between the
two species. A requirement for Nanog in direction of
self-renewal of human ES cells seems probable but
remains to be established. However, Oct4 appears to be
required to suppress extraembryonic differentiation in
human ES cells as it does in mouse ES cells (Hay et al.,
2004; Matin et al., 2004). Extrinsic signals that support
human ES cell self-renewal have yet to be definitively
identified, but may be different from those effective on
mouse ES cells. Several reports (Xu et al., 2001; Pera
et al., 2003; Amit et al., 2004) suggest that bFGF
promotes human ES cell self-renewal, an effect that has
not been observed on mouse ES cells. Human ES cells
can self-renew in the absence of exogenously added LIF
(Thomson et al., 1998; Reubinoff et al., 2000). However,
this does not necessarily mean that STAT3 activation is
not important for self-renewal of human ES cells. It is
possible that autocrine signalling through gp130 occurs
in these cultures and that the extent of this is sufficient
for the self-renewal of human but not mouse ES cells.
There is also a potentially trivial explanation for the
reported lack of effect of LIF on human ES cells in some
studies that stems from the widespread use of ESGRO, a
commercially available form of recombinant mouse
LIF. Mouse LIF does not bind to the human LIFR
(Layton et al., 1994). An alternative explanation is that
human ES cells express a higher effective level of Nanog
than mouse ES cells. Thus, human ES cells may not
require a cooperative interaction between STAT3 and
endogenous Nanog in order to self-renew efficiently.
Teratocarcinomas and ES cells
Teratocarcinomas are the classical stem cell tumour
(Pierce, 1967). In other words, they contain stem cells as
well as differentiated cells, whereas the related benign
tumours, teratomas, lack an undifferentiated compart-
ment. Of the two tumour types only the stem cell
containing teratocarcinomas can form secondary
tumours when serially transplanted. This concept of
cancers being composed of a heterogeneous mixture of
cell types including cancer stem cells has recently found
favour within the cancer research community (Pardal
et al., 2003) (see also the article by JE Dick in this issue).
It can explain the fact that chemotherapy often removes
the bulk of a tumour mass without preventing tumour
recurrence, suggesting the survival of a subset of cancer
stem cells. Therefore, it may be informative to contrast
the cryptic tumorigenic potential of epiblast and ES cells
with the overt malignancy of EC cells. An unanswered
question here is whether the epiblast cell is directly
tumorigenic, or are genetic or epigenetic changes
obligatory to confer continuous tumour growth and
transplantability? In this regard, it is interesting that the
majority of EC lines can self-renew in the absence of
LIF or of a feeder layer. In the past, there has been
strong selective pressure applied to cells during the
course of formation and serial transplantation of
teratocarcinomas and subsequent derivation of EC cells,
which historically was performed without LIF and in
many cases without feeders. It would be surprising
therefore if some genetic alterations did not occur. In
fact, EC cells exhibit a range of chromosomal abnorm-
alities, common among which is trisomy for chromo-
some 6. This is of interest because of the location of
Nanog on chromosome 6. In humans, testicular germ
cell tumours account for the majority of cancers in
young postpubertal men. These invariably exhibit
trisomy for chromosome 12 often present as a small
isochromosome, which contains the region syntenic to
mouse chromosome 6 on which Nanog is located
(Skotheim et al., 2002). Interestingly, during routine
culture hES cells repeatedly gain sequences from human
chromosome 17, whereas following subcloning or
attempts to culture hES cells in the absence of feeders,
duplication of chromosome 12 sequences occurs
(Draper et al., 2004). These observations have generated
some excitement given the fact that not only Nanog but
also Stella and GDF3 are localized to the same region of
synteny in rats as well as humans and mice (Payer et al.,
2003; Clark et al., 2004). It is possible that like the
related molecules GDF6 and BMP4, GDF3 could
enhance ES cell self-renewal, although at present there
is no direct evidence to support this notion. In contrast,
the case for an involvement of Stella is less clear (Payer
et al., 2003). However, the genetics of testicular germ cell
tumour susceptibility are controversial, with some
studies mapping the region encompassing Nanog, Stella
and GDF3 outwith the region of minimal duplication in
isochromosome 12 (Mostert et al., 1998; Rodriguez
et al., 2003; Skotheim and Lothe, 2003).
Recent studies have found comparatively high levels
of Oct4 during early stages of human testicular germ cell
tumorigenesis (Looijenga et al., 2003; Gidekel et al.,
2003). To investigate the significance of this expression,
further use was made of the cells carrying the
tetracycline regulatable Oct4 transgene referred to above
(Gidekel et al., 2003). In ES cell culture ZHTc6 cells
express B75% of wild type Oct4 protein levels when
cultured without tetracycline and B150% wild type
levels when cultured with tetracycline (Niwa et al.,
2000). ZHBTc4, cells only express Oct4 in the presence
of tetracycline and do so to about 60% wild-type levels
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(Niwa et al., 2000). Teratocarcinomas were formed
when these cells were subcutaneously injected into mice.
ZHTc6 cells produced tumours containing a greater
proportion of relatively undifferentiated tissue when the
recipients were allowed fresh drinking water as opposed
to water containing tetracycline. The tumour incidence
was lower when ZHBTc4 cells were injected and was
negligible when similarly injected mice were given
tetracycline to shut off transgene expression. More
significantly, when mice carrying ZHBTc4-derived
tumours were given tetracycline the tumours regressed.
These experiments not only show that the proportion of
relatively undifferentiated cells in a tumour can be
affected by the Oct4 level but also that Oct4 is required
continuously to maintain the malignant stem cell
component of teratocarcinomas.
Insight into the teratogenic nature of ES cells has
come from analysis of another of the ES cell-specific
transcripts identified by Yamanaka’s group. The corre-
sponding gene is X-linked and encodes a constitutively
active ras molecule termed Eras (Takahashi et al., 2003).
Mutations at codons 12, 59 and 63 of Hras render the
molecule constitutively active. When compared to Hras
both human and mouse Eras have amino-acid substitu-
tions at each of these codons. Importantly, Eras does
not engage the Raf–Mek–erk pathway, but does
stimulate PI3 kinase (see below). Eras ES cells expand
more slowly than unmutated ES cells despite continuing
to express Oct4 and retaining a normal morphology.
Moreover, when injected subcutaneously into nude mice
Eras ES cells produce significantly smaller tumours
than wild-type cells. This could indicate that Eras
tumours do not sustain a pluripotent compartment
and are teratomas rather than teratocarcinomas. This
would manifest in a loss in the ability of tumour cells to
produce secondary teratomas upon serial transfer,
although this remains untested. Intriguingly, Eras mice
show no abnormalities, indicating that Eras is dispen-
sable for the epiblast. However, it would be interesting
to know whether loss or mutation of Eras affects the
ability to derive ES cells de novo and whether Eras may
be involved in the nonpermissiveness for ES cell
derivation from certain mouse strains (Kawase et al.,
1994). A related issue is the timing and localization of
Eras expression in vivo and how this relates to the ease
with which ES cells can be isolated from embryos of
particular developmental stages (Brook and Gardner,
1997). A further point of interest is whether there is a
deficit in the ability of Eras embryos to survive a period
of implantational delay as has been demonstrated
for receptor components involved in LIF signalling
(Nichols et al., 2001). This would implicate Eras in the
STAT3 pathway. It is not currently known if Eras is a
downstream target of either STAT3 or Nanog.
ES cells have a rapid cell cycle with an unusually short
G1, possibly due to the fact that hypophosphorylated
retinoblastoma (Rb) is essentially undetectable (Burdon
et al., 2002). Transfection of an oncogenic form of Hras
caused growth retardation and differentiation of ES
cells (Cheng et al., 1998), an effect not seen with
overexpression of Eras (Takahashi et al., 2003). This is
consistent with a prodifferentiative rather than prolifer-
ative function for the SHP2–ras–MAPK pathway in ES
cells. Inhibitors of the MAPK pathway allow more
efficient ES cell self-renewal than mock-treated controls
(Burdon et al., 1999b). Furthermore, the efficiency of ES
cell derivation is enhanced by MAPK pathway inhibi-
tors (Buehr and Smith, 2003). The MAPK pathway is
linked to gp130 via binding of SHP2 to the same residue
that binds SOCS3. Consistent with a prodifferentiative
effect of the MAPK pathway, homozygous mutant
SHP2 ES cells have enhanced sensitivity to LIF (Qu and
Feng, 1998). Unlike oncogenic Hras, Eras does not
associate with Raf and does not activate the MAPK
pathway. However, Eras does interact with PI3K and
phosphorylation of the downstream target Akt was
decreased in Eras cells. The slow growth and reduced
size of teratomas produced by Eras cells could be
rescued by the expression of active PI3K. This fits with
the increased proliferation of ES cells lacking PTEN (the
phosphatase that hydrolyses PIP3) (Sun et al., 1999) and
with the incidence of testicular teratocarcinomas in
PTEN/ mice (Kimura et al., 2003). However, while the
PI3K inhibitor LY294002 increases the fraction of ES
cells that are in G0/G1phase of the cell cycle (Jirmanova
et al., 2002), the cell cycle status of Eras cells appears
unchanged. This suggests that PI3K may have a cell
cycle-independent effect on cell growth and could
indicate that LY294002 has an additional effect upon
ES cells that alters the cell cycle. The phenotype of
PTEN/ ES cells suggests that these cells may be
primed for unrelenting proliferation. The cells lack a
significant G1 phase and have constitutively high PIP3
levels. In fact, PTEN/ ES cells give rise to tumours
upon transplantation into mice that appear to consist
almost entirely of undifferentiated cells (Di Cristofano
et al., 1998). It may be that all that is required to achieve
tumorigenicity is a suppression of differentiation.
However, the stem cell nature of PTEN/ tumour cells
was not tested by serial transplantation.
It is notable that Eras activates a subset of the
pathways activated by more conventional ras molecules.
How general such restricted pathway activation is for
stem cells is unclear. However, it is interesting that
variant SHIP and Gab1 signalling molecules lacking
subcellular localization motifs have been identified in
haematopoietic and ES cells (Tu et al., 2001; Burdon
et al., 2002).
ES cell self-renewal circuit
The level of overexpression of Nanog is correlated to the
efficiency of the formation of cytokine-independent
undifferentiated ES cell colonies. A dosage effect is also
observed for STAT3 and Oct4. These observations can
be synthesized to provide a model of the contributions
of these molecules to ES cell self-renewal (Figure 4).
Mouse ES cell self-renewal requires the expression
of both Nanog and Oct4. Elimination of either of
these molecules results in a change in cell identity
from epiblast-like to the extraembryonic cell type
formed after the first (Oct4/) or second (Nanog/)
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differentiative decision to occur during embryogenesis.
Propagation of the pluripotent state normally requires
STAT3. When STAT3 activation is reduced either by
withdrawal of LIF or by interference with STAT3
function, cells cultured in serum differentiate into a
mixed cell population expressing markers of endoderm
and mesoderm. Overexpression of Nanog obviates the
requirement for extrinsic stimulation but also enhances
the efficiency of self-renewal in the presence of gp130
stimulation. This co-operative interaction between
Nanog and STAT3 suggests that when LIF is with-
drawn from genetically unmodified ES cells, there is a
decline in the ability of Nanog to function. Interestingly,
similar differentiation to that observed when STAT3
function is impaired is seen when Oct4 is overexpressed
in the presence of gp130 stimulation. This may indicate
an imbalance in the co-dependent Oct4- and Nanog-
mediated aspects of the self-renewal machinery. The
most parsimonious explanation of these observations is
that a co-factor that Oct4 requires for function is present
at limiting amounts and that this activity is stimulated
by LIF/STAT3. The fact that Nanog overexpression
enhances the efficiency of self-renewal in the presence of
STAT3 indicates that it is in fact limiting. A prediction
of this model would be that when Nanog is over-
expressed it could act to restrict the prodifferentiative
effect of elevated Oct4 levels. These considerations are
particularly interesting in light of a previously pro-
pounded model of ES cell self-renewal based on the
response of Oct4 target genes to alterations in the Oct4
level (Niwa, 2001). This model also predicts the
existence of a partner of Oct4, which is present in
limiting amounts in ES cells. This factor is proposed to
act on a subset of Oct4 target genes including Rex1 and
to be downstream of gp130 stimulation. If we modify
this model to say that the missing factor acts in
co-operation with rather than downstream of gp130,
then could the missing factor be Nanog? The Rex1
promoter is regulated by Oct4 and by an unknown
factor(s) termed Rox that binds at a site adjacent to the
Oct4-binding site (Ben-Shushan et al., 1998; Mitsui et al.,
2003). It has been proposed that this site may actually
bind Nanog (Mitsui et al., 2003). In this case, the
sequences corresponding to the Rox site are quite far
removed from the in vitro determined Nanog DNA-
binding site, although it is possible that the Nanog DNA
recognition site could be altered through interaction
with other adjacently binding factors.
Clearly, these suggestions can be tested experimen-
tally. An area that is likely to provide particular insight
into the mechanics of ES cell self-renewal is a
determination of whether or not there are direct
biochemical interactions between Nanog, Oct4 and
STAT3. If so, it will be important to understand how
these interactions are brought about and how they are
perturbed following alterations in the levels of the active
forms of the various factors.
A further aspect of self-renewal that needs to be
accommodated into a current model of ES cell self-
renewal is the dual roles of BMP. Smads can activate
non-neural differentiation in serum free cultures,
whereas STAT3 acts to repress the activation of these
pathways (Figure 4). Whether this occurs directly and/
or via an effect upon Smads is not clear. An interaction
between STAT3 and Smads has previously been
demonstrated in neural cells (Nakashima et al., 1999).
In this case, STAT3 and Smads coexist in a complex
bridged by p300/CBP. Such a complex may exist in ES
cells (Figure 4). It should be noted that the presence of
LIF switches BMP from a differentiative signal to a self-
renewal signal. An extreme hypothesis is that all that
STAT3 is required for in ES cells is to tie up Smads in a
p300/CBP bridged complex and by doing so reduce the
pool of free Smad available to activate differentiation
determining genes. This raises the question of whether
LIF would be required at all if cells could be removed
from all differentiation stimuli. In this respect, it may be
fruitful to enquire how nullipotent EC lines acquired
their resistance to differentiation stimuli. Finally, since
overexpression of Nanog liberates ES cell self-renewal
from the requirement for BMP signalling (Ying et al.,
2003), this places Nanog at centre stage in our current
attempts to unravel the mechanisms of ES cell self-
renewal.
In summary, we note that some components of ES cell
identity are unique to pluripotent cells (Nanog, Oct4),
Figure 4 Model of ES cell self-renewal signalling. Left, LIF and BMP act together to block differentiation. LIF activates STAT3 and
blocks non-neural differentiation. BMP blocks neural differentiation by induction of Id’s. The intrinsic transcriptional regulators
Nanog and Oct4 act to maintain an undifferentiated phenotype. Right, upon overexpression of Nanog, the requirement for extrinsic
signals to block differentiation is alleviated and ES cells self-renew constitutively
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whereas others (BMP, LIF) are generic and not stem cell
specific. We hypothesize that the intrinsic factors Nanog
and Oct4 are required to maintain epiblast identity and
that extrinsic factors (BMP, LIF) are required to block
germ-layer differentiation. It remains to be seen whether
illuminating the circuitry of ES cell self-renewal will be
informative in detail for tissue stem cell self renewal.
Perhaps, a conservation in principle is more likely:
unique intrinsic determinants imposing cell identity and
extrinsic signals suppressing activation of differentiation
pathways.
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